The non redundant roles are consistent with the in vitro and in vivo data collected on the synergistic activity of combining Chk1 and Wee1 inhibitors in solid tumors [13, 20–22] which was shown to be specific for tumor cells, thus enhancing the therapeutic potential of this combination [13, 20]. The gene discussed is WEE1; the disease is neoplasm.